{{medical}}
{{drugbox
| IUPAC_name        = 8-氯-5-(2-環丙乙炔)-5-(三氟甲基)- 4-氧雜-2-雜環 [4.4.0]去- 7,9,11-三烯-3-酮
| image             = Efavirenz.svg
| image2 = Efavirenz 3D balls 1fk9.png
| width             =150

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 154598-52-4
| ATC_prefix = J05
| ATC_suffix = AG03
| PubChem = 64139
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00625
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 57715
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JE6H2O27P8
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00896
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 119486
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 223228
| PDB_ligand = EFZ
| NIAID_ChemDB = 032934
| synonyms          = [[CADN|CADN]]通用名：依法韦仑<br/>
[[INN|INN]]通用名:[http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/webglimpse.cgi?ID=16&whole=ON&cache=yes&query=Efavirenz Efavirenz]
| C = 14 | H = 9 | Cl = 1 | F = 3 | N = 1 | O = 2
| molecular_weight  = 315.675 [[克|g]]/[[摩尔|mol]]
| bioavailability   = 
| protein_bound = 99.5-99.75%
| metabolism = [[肝|肝]] ([[CYP3A4|CYP3A4]] and [[CYP2B6|CYP2B6]]-mediated)
| elimination_half-life = 40-55小時 小时
| excretion         = [[腎臟|腎臟]]與[[排遺|排遺]]
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  D
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  POM
| legal_US          =  Rx-only
| legal_status      = 
| routes_of_administration = 口服
}}
<!-- FAIR USE of Efavirenz_Sustiva.gif: see image description page at http://en.wikipedia.org/wiki/Image:Efavirenz_Sustiva.gif for rationale --> 
'''依法韦仑'''（英文：Efavirenz）是一种抵抗[[人類免疫缺乏病毒|人類免疫缺乏病毒]]的特效药物。<!-- favirenz -->'''依法韦仑'''的商业名称为'''Sustiva®''' 或'''Stocrin®'''，它是一种属于[[非核苷逆轉錄酶抑制物|非核苷逆轉錄酶抑制物]]（NNRTI—non-nucleoside reverse transcriptase inhibitor）类别的药物，<!-- and is used as part of highly active antiretroviral therapy ([[HAART|HAART]]) for the treatment of a human immunodeficiency virus ([[HIV|HIV]]) type 1.-->可在高活性抗逆转病毒疗法中使用，进行医治甲类人体免疫性病毒（HIV type 1）。

依法韦仑可用于医治未被医治过的[[HIV|HIV]]感染者，它的优点是能与lamivudine、<!-- combination with -->zidovudine或tenofovir等药物共用作为比较优异的NNRTI-培养基（regimen）。<!--
For HIV infection that has not previously been treated, efavirenz and [[lamivudine|lamivudine]] in combination with [[zidovudine|zidovudine]] or [[tenofovir|tenofovir]] is the preferred NNRTI-based regimen.-->

依法韦仑也时常被与其他药物联合使用以防止[[HIV|HIV]]在高危人群当中的感染与扩散。<!--
Efavirenz is also used in combination with other [[antiretroviral|antiretroviral]] agents as part of an expanded [[postexposure_prophylaxis|postexposure prophylaxis]] regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

此段与文章后面服用指南重复:
The usual adult dose is 600 [[Milligram|mg]] once a day taken on an empty stomach at bedtime. 
移动至后部:
Efavirenz was combined with the popular [[HIV|HIV]] medication [[Truvada|Truvada]] and approved by the [[FDA|FDA]] in July of 2006, under the brand name [[Atripla|Atripla]]. This was done to simplify the drug regimen for the many patients who take these two medications in combination.-->

==历史==
经过多年研制与临床实验，1998年9月18日依法韦仑被[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）通过鉴定。它成为第3种被FDA通过鉴定的非核苷逆转录酶抑制剂。<ref>[http://www.fda.gov/bbs/topics/NEWS/NEW00654.html FDA APPROVES NEW DRUG TO TREAT HIV, AIDS] {{Wayback|url=http://www.fda.gov/bbs/topics/NEWS/NEW00654.html |date=20090513073506 }}，FOOD AND DRUG ADMINISTRATION</ref>

==用途==
依法韦仑是抗[[人類免疫缺乏病毒|人類免疫缺乏病毒]][[感染|感染]]的药品，它从不单独使用，而是与其他药物一起组成复合剂，<!-- is used to treat [[HIV|HIV]] infection.  It is never used alone and is always given in combination with other drugs.  The decision on when to start treatment should take into account [[CD4_count|CD4 count]], [[HIV_viral_load|HIV viral load]], treatment history, resistance profiles and patient preference.-->在决定开始药物治疗时应当考虑以下因素：[[CD4读数|CD4读数]]、[[HIV病源体荷载|HIV病源体荷载]]（{{lang|en|HIV viral load}}）、[[病人|病人]]的[[诊治|诊治]][[历史|历史]]、[[抗药性|抗药性]]及其个人意愿。

2006年<!--Since the preliminary publication of the results of the -->[[ACTG_5142|ACTG 5142]]号试验的初始结果公布，该试验将依法韦仑与<!-- trial in 2006 which compared efavirenz against -->[[lopinavir|lopinavir]]相对照，<!-- efavirenz has been used as first line treatment in preference to the [[protease_inhibitor|protease inhibitor]]s.  The [[ACTG_5095|ACTG 5095]] trial showed that the potency of efavirenz is maintained at all [[CD4_count|CD4 count]]s and [[HIV_viral_load|HIV viral load]]s.-->依法韦仑被用于第一线治疗各种蛋白酶抑制体，[[ACTG_5095|ACTG 5095]]号试验表明依法韦仑在维持[[CD4读数|CD4读数]]与[[HIV病源荷载|HIV病源荷载]]具有潜力 。

==作用機理== 
<!-- 异型分子式 :
[[File:efavirenz.png|center]]<br /><small>SUSTIVA</small>
-->
依法韦仑属于[[非核苷逆轉錄酶抑制物|非核苷逆轉錄酶抑制物]]（NNRTI—non-nucleoside reverse transcriptase inhibitor）<!--Efavirenz falls in the--non-nucleoside reverse transcriptase inhibitor（NNRTI）-->类别的抗逆转病毒（antiretrovirals）药物，<!-- class of . -->基于核苷的RTI与非基于核苷的RTI均意图抑制同一个目标<!--Both nucleoside and non-nucleoside RTIs inhibit the same -->（target），即逆转录酶（reverse transcriptase enzyme）。这种酶是从RNA转录到DNA中，它对于病毒的繁殖极其重要。<!-- the [[reverse_transcriptase|reverse transcriptase]] enzyme, an essential viral enzyme which transcribes viral RNA into DNA.-->

NNRTI与基于核苷的RTI的不同之处是，前者捆绑于NNRTI鞘体当中，后者捆绑于酶体的活性面。<!-- Unlike nucleoside RTIs, which bind at the enzyme's active site, NNRTIs bind  within a pocket termed the NNRTI pocket. -->

依法韦仑对于乙类人体免疫性病毒（HIV type 2）无效。<!--Efavirenz is not effective against HIV-2,-->原因是：<!-- as the pocket of the -->HIV-2鞘部的逆转基元（reverse transcriptase）结构不同。因此对NNRTI类药物具有其内在的抗药性。<!-- has a different structure, which confers intrinsic resistance to the NNRTI class.--><ref>{{cite journal | author=Ren J, Bird LE, Chamberlain PP, ''et al.'' | year=2002 | title=Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors | journal=Proc Natl Acad Sci USA | volume=99 | pages=14410–15 | id=PMID 12386343}}</ref>

由于所有的NNRTI都捆绑于同一个NNRTI鞘体当中，<!--As all NNRTIs bind within the same pocket, -->对于依法韦仑具有抗药性的病毒变种（viral strains）亦对其他NNRTI类药物（如：[[nevirapine|nevirapine]]和[[delavirdine|delavirdine]]）具有抗药性，<!-- which are resistant to efavirenz are usually also resistant to the other NNRTIs, [[nevirapine|nevirapine]] and [[delavirdine|delavirdine]]. The most common mutation observed after efavirenz treatment is K103N, -->当采用药物治疗之后最常见的病毒突变种型（mutation）为K103N型，这个突变种型通常也能在采用其他NNRTI类药物之后被观察到。<!--which is also observed with other NNRTIs.--><ref>{{Cite web |url=https://packageinserts.bms.com/pi/pi_sustiva.pdf |title=Sustiva（中文商标名：希宁，即efavirenz）药囊与药片产品资讯（2005年4月）<!-- capsules and tablets. Product information (April 2005)--> |accessdate=2007-05-07 |archive-date=2007-09-27 |archive-url=https://web.archive.org/web/20070927200623/https://packageinserts.bms.com/pi/pi_sustiva.pdf |dead-url=no }}</ref>

==使用剂量==
成人通常可使用剂量的为每天600微克，需空腹在睡前服用。<!--
The usual adult dose of efavirenz is 600mg per day (usually given at bedtime); or 800mg daily when given concurrently with [[rifampicin|rifampicin]] as part of treatment of co-infection with [[tuberculosis|tuberculosis]].-->或在医治并发的肺结核病时，将800微克与rifampicin并服。

2006年美国药物及食品管理局（FDA）批准将依法韦仑与另一常用医治[[HIV|HIV]]的药物Truvada联合使用。<!-- 
Efavirenz was combined with the popular HIV medication Truvada and approved by the FDA in July of 2006, under the brand name-->新混成药的品牌是：Atripla。<!-- This was done to simplify the drug regimen for the many patients who take these two medications in combination.
-->此项批准的原因很简单，很多病人在接受医治当中的确是需要将以上两种药物混合使用。

==交互作用==
*依法韦仑<!--Efavirenz is metabolized in the liver,-->会在肝脏中发生代谢变化，它对于[[细胞色素P450|细胞色素P450]]体系中的[[CYP3A4|3A4]]同构类型（isoform）同时具有抑制与诱发的作用。<!-- and possesses both inhibitory and inducing effects on the [[CYP3A4|3A4]] isoform of the [[cytochrome_P450|cytochrome P450]] system. -->这也意味着Efavirenz到达肝脏后会与他种药物在代谢中产生互相增减的作用，所以在将Efavirenz与其他药物混合使用时应酌量增加或减少剂量。<!--This means efavirenz may interact with other drugs metabolized in the liver, requiring either increased or decreased dosages.-->
*依法韦仑会降低多数蛋白酶抑制体的血糖含量水准。<!--Efavirenz lowers blood levels of most [[protease_inhibitor_(pharmacology)|protease inhibitors]]. -->所以使用它时或许需要同时添加amprenavir、atazanavir、indinavir的剂量。<!--Dosages of [[amprenavir|amprenavir]], [[atazanavir|atazanavir]], or [[indinavir|indinavir]] may need to be increased. -->使用它之后血液中的saquinavir含量也会骤减，所以两种药物不得同时使用。<!--The blood levels of [[saquinavir|saquinavir]] are dramatically lowered, so that the two drugs cannot be used simultaneously.-->
*[[貫葉連翹|貫葉連翹]]<!--圣约翰-->制剂和[[蒜苗|蒜苗]]添加剂也有可能降低依法韦仑在血液中的含量。<!-- and [[garlic|garlic]] supplements may decrease efavirenz blood levels.--[[Efavirenz|Efavirenz]]-->

==副作用==
*常有以下精神病理学症状：<!--Psychiatric symptoms, including [[insomnia|insomnia]], [[confusion|confusion]], [[memory_loss|memory loss]], and [[depression_(mood)|depression]], are common-->失眠症、混淆、错乱、记忆力丧失、情绪消沉等。
*也许还会出现皮疹、恶心、晕眩和头痛。<!--[[Rash|Rash]], [[nausea|nausea]], [[dizziness|dizziness]] and [[headache|headache]] may occur-->
*依法韦仑有可能会导致新生婴儿缺陷，所以不得用于有怀孕机遇的妇女。<!-- Efavirenz can cause [[birth_defects|birth defects]] and should not be used in women who might become pregnant--><ref name="dhhs">DHHS panel. 针对成年及青少年甲型人体免疫性病毒（HIV-1）感染者的抗逆转性病毒药物使用指南，该资讯由美国政府爱滋病资讯网（AIDSInfo）免费提供于2006年4月 - Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). ([http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 Available for download from AIDSInfo] {{Wayback|url=http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 |date=20060506193229 }})</ref>
*对婴儿使用的安全性亦尚未得到证实<!-- 确认?? Safety in children has not been established-->
*使用依法韦仑<!--Use of efavirenz can produce a [[false_positive|false positive]] result in some urine tests for [[marijuana|marijuana]]-->还有可能导致对[[大麻|大麻]]物质的尿检呈虚假的[[阳性|阳性]]。

<!-- The following section may be redundant, since much of its information is already contained in the drugbox.-->
==化学结构和化学状态==
依法韦仑的化学描述式为：<!--Efavirenz is chemically described as -->(S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one.<BR>经验公式(empirical formula)为： C<sub>14</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>2</sub>.

常态下的依法韦仑是白色或粉红色晶状粉末，<!--Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68 g/mol. It is practically [[insoluble|insoluble]] in water .
-->分子量315.68 g/mol，水溶性为(<10 µg/mL)，<!--实际上-->所以在实质上它是不溶解于水的。

==参考文献==
<references/>

==外部链接==
*[http://www.sustiva.com/managehiv/sustiva/home/index.jsp?BV_UseBVCookie=Yes 依法韦仑生产厂商的网址] {{Wayback|url=http://www.sustiva.com/managehiv/sustiva/home/index.jsp?BV_UseBVCookie=Yes |date=20070623144519 }} 
*[https://web.archive.org/web/20070927200623/https://packageinserts.bms.com/pi/pi_sustiva.pdf 依法韦仑的处方资讯]

{{Hallucinogens}}
{{Depressogenics}}
<!--
{{Antivirals}}
-->

[[Category:非核苷逆转录酶抑制剂|Category:非核苷逆转录酶抑制剂]]
[[Category:炔烃|Category:炔烃]]
[[Category:百时美施贵宝|Category:百时美施贵宝]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:苯并恶嗪|Category:苯并恶嗪]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:有机氯化合物|Category:有机氯化合物]]
[[Category:氨基甲酸酯|Category:氨基甲酸酯]]
[[Category:环丙基化合物|Category:环丙基化合物]]
[[Category:三氟甲基化合物|Category:三氟甲基化合物]]
[[Category:肝毒素|Category:肝毒素]]